Welcome Letter
Dear Colleagues,
We are delighted to extend a warm invitation to the 3rd RNA Horizons Conference, a distinguished gathering dedicated to advancing the transformative potential of RNA technology in cancer medicine. Following the resounding success of our inaugural meeting, where we explored the exciting frontiers of RNA research, we are eager to convene once more.
In collaboration with our esteemed partners at CANCERNA, we invite you to join us in Munich, Germany, from September 16-18, 2026.
This conference will provide a unique platform for:
- Exploring cutting-edge advancements: Delving into the latest research on RNA system biology, including RNA splicing, editing, and processing.
- Discovering novel therapeutic avenues: Unlocking the potential of RNA therapeutics to modulate cancer, generate immunogenic transcripts, and target cancer vulnerabilities.
- Fostering interdisciplinary collaboration: Connecting with a diverse community of researchers, fostering meaningful partnerships between academia and industry.
We believe that through collaborative efforts, we can accelerate the translation of groundbreaking RNA research into impactful cancer therapies.
To learn more about the insights and discussions from our first meeting, please visit www.rnahorizons.com.
We look forward to welcoming you to Munich in September 2026.
RNA Horizons 2026 Organizing Committee
Head of The Hadassah Cancer Research Institute (HCRI)
Hadassah Hebrew University Medical Center, Jerusalem, Israel
Principal Investigator
Hebrew University-Hadassah Medical School, Jerusalem, Israel, and University of Pennsylvania, USA
Ernesto Guccione
Principal Investigator, The Guccione Lab
Icahn School of Medicine at Mount Sinai, USA
Claudio Sette
Principal Investigator
Catholic University of the Sacred Heart, School of Medicine, Italy
